NEIKA COUGHLIN: Open Payments
NPI 1982673331 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,374 in 80 payments from 21 companies in 2025. Trend: 2023 $371 · 2024 $1,450 · 2025 $4,374
Food & beverage: $3,127Travel & lodging: $1,175Education: $72
| Company | Payments | Amount |
|---|---|---|
| Medtronic, Inc. | 17 | $1,698 |
| Amgen Inc. | 12 | $591 |
| Abbott Laboratories | 3 | $339 |
| Novartis Pharmaceuticals Corporation | 10 | $242 |
| ABIOMED | 2 | $218 |
| BridgeBio Pharma, Inc. | 3 | $212 |
| E.R. Squibb & Sons, L.L.C. | 6 | $175 |
| Regeneron Healthcare Solutions, Inc. | 3 | $152 |
| HEARTFLOW, INC. | 1 | $146 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $141 |
Products named: REPATHA, LEQVIO, Attruby, SYMPLICITY G3, AVEIR, EVKEEZA, FFRct, Kerendia.
Industry payments across NE — which companies pay providers there.
